Abstract
Prolactinomas (PPAs) are the most common type of secretory pituitary adenomas. The majority of prolactinomas are found in women on evaluation of amenorrhea, infertility, and new onset or persistent lactation after discontinuation of breastfeeding. Although galactorrhea may also be a sentinel symptom in males, this is not as common, and is often preceded by sexual dysfunction. Diagnosis may not occur, particularly in males or postmenopausal women, until midlife when tumor growth impacts the optic chiasm and/or visual deficits are found, prompting ophthalmology review and subsequent imaging. Likewise, pituitary adenomas may be an incidental finding on a head CT or MRI obtained during a workup for headaches, after a head trauma, or other symptoms.
In addition to a brain MRI to determine tumor size, location, and characteristics, all pituitary hormonal expressions are usually evaluated. Both macroadenomas (MA) and microadenomas (mA) may cause anterior pituitary hormone deficits, and further dynamic testing may be needed. Posterior pituitary hormone deficits are quite rare and would only occur with very large tumors. Prolactin (PRL) assays may vary, so obtaining a diluted PRL level is necessary when levels are high in patients with large tumors (usually >3 cm diameter) to avoid misinterpretation of results secondary to the assay “hook effect.” Evaluation of macroprolactin (biologically inactive PRL) may also be needed in patients without symptoms in order to avoid unnecessary treatment.
Treatment may depend on presenting symptoms and deficiencies. However, prolactinomas are most frequently responsive to dopamine agonist (DA) medications that both normalize prolactin levels and can shrink tumors. Normalization of PRL most often restores fertility, resolves galactorrhea, and significantly improves headaches. Likewise, visual deficits will often resolve or significantly improve with tumor shrinkage. Intolerance or resistance to dopamine agonists, tumor growth while on dopamine agonists, co-secretion with another hormone or a need for a biopsy for histopathology are criteria for transsphenoidal tumor resection. Best postoperative results are achieved by an experienced neurosurgeon. However, treatment with medical therapies (DA), other hormone replacements, or radiation therapy may still be needed postoperatively to control prolactin levels or residual tumor growth.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AP:
-
Anterior pituitary
- DA:
-
Dopamine agonist
- FSH:
-
Follicle stimulating hormone
- GH:
-
Growth hormone
- GnRH:
-
Gonadotropin releasing hormone
- ICD:
-
Impulse control disorder
- LH:
-
Luteinizing hormone
- MA:
-
Macroadenomas/adenomas >1 cm
- mA:
-
Microadenomas/adenomas <1 cm
- MRI:
-
Magnetic resonance imaging
- PA:
-
Pituitary adenoma
- PPA:
-
Prolactin producing adenoma/prolactinoma
- PRF:
-
Prolactin releasing factors
- PRL:
-
Prolactin
- QoL:
-
Quality of life
References
Barlier A, Jaquet P. Quinagolide – a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol. 2006;154:187–95.
Bernard V, Young J, Chanson P, Binart N. New insights in prolactin: pathological implications. Nat Rev Endocrinol. 2015;11(5):265–75. https://doi.org/10.1038/nrendo.2015.36. Epub 2015 Mar 17. Review. PMID:25781857
Bridges, RS. Prolactin: Regulation and actions. Neuroscience 2018. Online Jan 2018. https://doi.org/10.1093/acrefore/9780190264086.013.61.
Bronstein MD. Prolactinomas and pregnancy. Pituitary. 2005;8:31–8. https://doi.org/10.1007/s11102-005-5083-4.
Catli G, Abaci A, Altincik A, Demir K, Can S, Buyukgebiz A, Bober E. Hyperprolactinemia in children: clinical features and long-term results. J Pediatr Endocrinol Metab. 2012;25(11–12):1123–8.
Catli G, Abaci A, Bober E, Büyükgebiz A. Clinical and diagnostic characteristics of hyperprolactinemia in childhood and adolescence. J Pediatr Endocrinol Metab. 2013;26(1–2):1–11. https://doi.org/10.1515/jpem-2012-0327.
Chahal J, Schlechte J. Hyperprolactinemia. Pituitary. 2008;11:141. https://doi.org/10.1007/s11102-008-0107-5.
Chang FE, Dodds WG, Sullivan M, Kim MH, Malarkey WB. The acute effects of exercise on prolactin and growth hormone secretion: comparison between sedentary women and women runners with normal and abnormal menstrual cycles. J Clin Endocrinol Metab. 1986 Mar;62(3):551–6.
Chanson P, Maiter D. Prolactinoma. In: Melmed S, editor. The pituitary. 4th ed. London: Elsevier; 2017. p. 467–514.
Chanson P, Borson-Chazot F, Chabre O, Estour B. Drug treatment of hyperprolactinemia. Ann Endocrinol (Paris). 2007;68(2–3):113–7. Epub 2007 May 29. Review
Chanson P, Borson-Chazot F, Chabre O, Estour B. Drug treatment of hyperprolactinemia. Ann Endocrinol. 2007;68(2–3):e30–4.
Christensen SE, Jørgensen O, Møller J, Møller N, Orskov H. Body temperature elevation, exercise and serum prolactin concentrations. Acta Endocrinol. 1985;109(4):458–62.
Ciccarelli A, Guerra E, De Rosa M, Milone F, Zarrilli S, Lombardi G. PRL secreting adenomas in male patients. Pituitary. 2008;8:29–32.
Cocks Eschler D, Javanmard P, Cox K, Geer EB. Prolactinoma through the female life cycle. Endocrine. 2018;59:16.
Colao A, Di Sarno A, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148(3):325–31.
Colao A, Abs R, Bárcena DG, Chanson P, Paulus W, Kleinberg DL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol. 2008;68:66–71.
Comtois R, Robert F, Hardy J. Immunoradiometric assays may miss high prolactin levels. Ann Intern Med. 1993;119:173.
Crosignani PG, Ferrari C, Scarduelli MC, Picciotti R, Malinverni AC. Spontaneous and induced pregnancies in hyperprolactinemic women. Obstet Gynecol. 1981;58(6):708–13.
Dalzell JR, Jackson E, Gardner RS. An update on peripartum cardiomyopathy. Exp Rev Cariovasc Ther. 2011;9:1155–60. https://doi.org/10.1586/erc.11.121.
de Laat JM, Dekkers OM, Pieterman CR, Kluijfhout WP, Hermus AR, Pereira AM, van der Horst-Schrivers AN, Drent ML, Bisschop PH, Havekes B, de Herder WW, Valk GD. Long-term natural course of pituitary tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab. 2015;100(9):3288–96. https://doi.org/10.1210/JC.2015-2015. Epub 2015 Jun 30
Farzami MR, Aliasgharpour M. Chemiluminescence systems; do all lead to same results in prolactin analysis? J Diabetes Metab Disord. 2017;16:24. https://doi.org/10.1186/s40200-017-0305-7. Published online 2017 June 5. PMCID: PMC5460514
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80(4):1523–631.
Gillam M, Molitch M. Prolactin. In: Melmed S, editor. The pituitary. 3rd ed. London: Elsevier; 2011a. p. 119–66. https://doi.org/10.1016/B978-0-12-380926-1.10015-X.
Gillam M, Molitch M. Prolactinoma. In: Melmed S, editor. The pituitary. 3rd ed. London: Elsevier; 2011b. p. 475–531. https://doi.org/10.1016/B978-0-12-380926-1.10015-X.
Glezer A, Bronstein MD. Prolactinoma. Endocrinol Metab Clin N Am. 2015;44:71–8.
Gorvin CM. The prolactin receptor: diverse and emerging roles in pathophysiology. J Clin Translational Endocrinol. 2015;2:85e91.
Grattan D. The hypothalamo-prolactin axis. J Endocrinol. 2015;226:T101–22.
Grossman A, Besser GM. Prolactinomas. Br Med J. 1985;20:182–4.
Hilfiker-Kleiner D, Kaminski D, Podewski E, Bonda T, Schaefer A, Silwa K, Foster O, Quint A, Lanmesser U, Doerries C, et al. A cathespin D-cleaved 16kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2006;128:589–600. https://doi.org/10.1016/j.cell.2016.12.036.
Hilfiker-Kleiner D, Struman I, Hoch M, Podswski E, Silwa K. 16kDa prolactin and bromocriptine in postpartum cardiomyopathy. Curr Heat Fail Rep. 2012;9:174–82. https://doi.org/10.1007/s11897-012-0095-7.
Hoffmann A, Adelmann S, Lohle K, Claviez C, Müller HL. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur J Pediatr. 2018;177:125–32. https://doi.org/10.1007/s00431-017-3042-5.
Horseman ND, Gregerson KA. Prolactin actions. J Mol Endocrinol. 2014;52:R95–R106.
Hu Y, Ding Y, Yang M, et al. Serum prolactin levels across pregnancy and the establishment of reference intervals. Clin Chem Lab Med. 2017;56(5):803–7. https://doi.org/10.1515/cclm-2017-0644. Retrieved 19 Jan 2018
Ignacak A, Kasztelnik M, Sliwa T, Korbut RA, Rajda K, Guzik TJ. Prolactin - not only lactotrophin a “new” view of the “old” hormone. J Physiol Pharmacol. 2012;63(5):435–43.
Ikeda H, Watanabeb K, Tominagac T, Yoshimotoc T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin Neurol Neurosurg. 2013;115:1621–5.
Jankowski PP, Crawford JR, Khanna P, Malicki DM, Ciacci JD, Levy ML. Pituitary tumor apoplexy in adolescents. World Neurosurg. 2015;83(4):644–51.
Jeffcoate SL, Bacon RRA, beastall GH, Diver MJ, Franks S, Seth J. Assays for prolactin: guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem. 1986;23:638–51.
Jethwa PR, Patel TD, Hajart AF, Eloy JA, Couldwell WT, Liu JK. Surgery versus medical therapy in the management of microprolactinoma in the United States. World Neurosurg. 2016;87:65–76.
Johnson MD, Woodburn CJ, Vance ML. Quality of life in patients with a pituitary adenoma. Pituitary. 2003;6(2):81–7.
Kars M, Pereira AM, Smit JW, Romijn JA. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. Eur J Intern Med. 2009;20:387–93.
Kiive E, Maaroos J, Shlik J, Tõru I, Harro J. Growth hormone, cortisol and prolactin responses to physical exercise: higher prolactin response in depressed patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2004;28(6):1007–13.
Kim Y-M, Seo GH, Kim Y-M, Choi J-H, Yoo H-W. Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases. Endocrine J [Advance publication]. Released December 27, 2017, Online ISSN 1348-4540, Print ISSN 0918-8959. https://doi.org/10.1507/endocrj.EJ17-0268. https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ17-0268/_article/-char/en
Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977;296(11):589–600.
Klibanski A. Prolactinomas. N Engl J Med. 2010;362(13):1219–26.
Low MJ. Neuroendocrinology. In: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, editors. Williams textbook of endocrinology. 13th ed. Philadelphia: ScienceDirect Elsevier; 2016. p. 109–75.
Majumdar A, Mangal NS. Hyperprolactinemia. J Hum Reprod Sci. 2013;6(3):168–75. https://doi.org/10.4103/0974-1208.121400.
Marano RJ, Ben-Jonathan N. Minireview: extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol. 2014;28(5):622–33. https://doi.org/10.1210/me.2013-1349.
Medicines and Healthcare Regulatory Agency. WHO International Standard Prolactin, Human. Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified NIBSC code: 83/573 (Version 5.0, Dated 10/11/2016). http://www.nibsc.org/documents/ifu/83-573.pdf. Accessed 28 Feb 2018.
Melmed S, Felipe F, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, JAH W. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88. https://doi.org/10.1210/jc.2010-1692.
Mitani S, Amano I, Takatsuru Y. High prolactin concentration during lactation period induced disorders of maternal behavioral in offspring. Psychoneuroendocrinology. 2018;88:129–35.
Molitch M. Medication-induced hyperprolactinemia. Mayo Clin Proc. 2005;80(8):1050–7.
Molitch M. Diagnosis and treatment of pituitary adenomas: a review. JAMA. 2017;317(5):516–24. https://doi.org/10.1001/jama.2016.19699.
Noel GL, Suh HK, Stone JG, Frantz AG. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab. 1972;35(6):840–51. https://doi.org/10.1210/jcem-35-6-840.
Noel GL, Suh HK, Frantz AG. Prolactin release during nursing and breast stimulation in postpartum and non postpartum subjects. J Clin Endocrinol Metab. 1974;38(3):413–23. https://doi.org/10.1210/jcem-38-3-413.
Noronha S, Stokes V, Karavitaki N, Grossman A. Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine. 2016;51:205–10. https://doi.org/10.1007/s12020-015-0727-2.
Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol. 1999;51:119.
Ranganthan M, Braey G, Pittman B, Cooper T, Perry E, Krystan J, D’Souza DC. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology. 2009;203(4):737–944. https://doi.org/10.1007/s00213-008-1422-2.
Rodman EF, Molitch ME, Post KD, Biller BJ, Reichlin S. Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma. JAMA. 1984;252(7):921–4. https://doi.org/10.1001/jama.1984.03350070039020.
Romijn JA. Hyperprolactinemia and prolactinoma. Handb Clin Neurol. 2014;124:185–95. https://doi.org/10.1016/B978-0-444-59602-4.00013-7. Review. PMID: 25248588
Sairenjia TJ, Ikezawaa J, Kanekob R, Masudaa S, Uchidac K, Takanashia Y, Masudaa H, Sairenjid T, Amanoa I, Takatsurua Y, Sayamae K, Haglundf K, Dikicg K, et al. Maternal prolactin during late pregnancy is important in generating nurturing behavior in the offspring. Proc Natl Acad Sci U S A. 2017;114(49):13042–7.
Salenave S, Ancelle D, Bahougne T, Raverot G, Kamenický P, Bouligand J, Guiochon-Mantel A, Linglart A, Souchon P-F, Nicolino M, Young J, Borson-Chazot F, Delemer B, Chanson P. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100(3):1177–86. https://doi.org/10.1210/jc.2014-3670.
Sarwar KN, Huda MS, Van de Velde V, Hopkins L, Luck S, Preston R, McGowan BM, Carroll PV, Powrie JK. The prevalence and natural history of pituitary hemorrhage in prolactinoma. J Clin Endocrinol Metab. 2013;98(6):2362–7. https://doi.org/10.1210/jc.2013-1249. Epub 2013 Apr 12
Smith TP, Kavanagh L, Healy ML, McKenna TJ. Technology insight: measuring prolactin in clinical samples. Nat Clin Pract Endocrinol Metab. 2007;3(3):279–89.
Spiegel K, Follenius M, Simon C, Saini J, Ehrhart J, Brandenberger G. Prolactin secretion and sleep. Sleep. 1994;17(1):20–7.
Stewart JK, Clifton DK, DJ K, Rogol AD, Jaffe T, Goodner CJ. Pulsatile release of growth hormone and prolactin from the primate pituitary in vitro. Endocrinology. 1985;116(1):1–5.
Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007;3(5):929–51.
Toulis KA, Robbins T, Reddy N, Balachandran K, Gokhale K, Wijesinghe H, Cheng KK, Karavitaki N, Wass J, Nirantharakumar K. Males with prolactinoma are at increased risk of incident cardiovascular disease. Clin Endocrinol. 2018;88:71–6. https://doi.org/10.1111/cen.13498.
Zygourakis CC, Imber BS, Chen R, Han SJ, Blevins L, Molinaro A, Kahn JG, Aghi MK. Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J Neurol Surg B Skull Base. 2017;78(2):125–31. https://doi.org/10.1055/s-0036-1592193. Epub 2016 Sep 27
Key Reading
Melmed S, Felipe F, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, JAH W. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273–88. https://doi.org/10.1210/jc.2010-1692.
Gillam M, Molitch M. Proactin. In: Melmed S, editor. The Pituitary. 3rd ed. London: Elsevier; 2011. p. 119–66. https://doi.org/10.1016/B978-0-12-380926-1.10015-X.
Chanson P, Maiter D. Prolactinoma. In: Melmed S, editor. The pituitary. fourth ed. London: Elsevier; 2017. p. 467–514.
Glezer A, Bronstein MD. Prolactinoma. Endocrinol Metab Clin N Am. 2015;44:71–8.
Romijn JA. Hyperprolactinemia and prolactinoma. Handb Clin Neurol. 2014;124:185–95. https://doi.org/10.1016/B978-0-444-59602-4.00013-7. Review. PMID: 25248588
Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007;3(5):929–51.
Acknowledgement
The author acknowledges Mark Molitch MD who is the Professor of Medicine (Endocrinology), Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, IL USA.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yedinak, C. (2019). Prolactin Producing Adenomas: Prolactinomas and Hyperprolactinemia. In: Llahana, S., Follin, C., Yedinak, C., Grossman, A. (eds) Advanced Practice in Endocrinology Nursing. Springer, Cham. https://doi.org/10.1007/978-3-319-99817-6_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-99817-6_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99815-2
Online ISBN: 978-3-319-99817-6
eBook Packages: MedicineMedicine (R0)